A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2013
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 08 Apr 2013 Results will be presented at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), according to a Janssen R&D Ireland media release.
- 09 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.